Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome
Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific leadership in Alport Syndrome. The new CAB brings unparalleled expertise […] Read More
Drug Discovery and the Impact of mAbs
In another significant mAb collaboration. Fibrocor Therapeutics agreed a research and development (R&D) collaboration with the McQuade Center for Strategic Research and Development (MSRD) in March 2024 to advance its Alpon Syndrome programme. Phase I […]
Read More
Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program
Agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase 1b Deal is a major step forward for Fibrocor’s plans to […] Read More